Delineating the mechanisms underlying heart valve endothelial repair
Delineating the mechanisms underlying heart valve endothelial repair
批准号:
10586074
负责人:
VOLKHARD LINDNER
金额:
$49.35万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-03-15 至 2026-02-28
关键词:
AffectAgingAortic InjuryAortic RuptureAortic Valve StenosisCellsChildhoodClinicalClinical ManagementCommunicationCongenital Heart DefectsCongestive Heart FailureDeteriorationDiagnosisDiseaseEndothelial CellsEndotheliumFunctional disorderGenetic TranscriptionHeart Valve DiseasesHeart ValvesHourHumanImpairmentIn VitroIndividualInfantInjuryLeftModelingMolecularMusOperative Surgical ProceduresOryctolagus cuniculusOutcomeParacrine CommunicationPathologyPatientsPediatricsPopulationPredispositionProcessProliferatingProteomicsPublic HealthReportingSignal TransductionSiteTestingTherapeuticTissuesTreatment StepWorkaortic valvedesigneffective therapyendothelial dysfunctionendothelial repairfollow-upfunctional disabilityhistological studiesimprovedin vivoinnovationinterstitialinterstitial cellmigrationmouse modelneonatenovel therapeutic interventionpreventrepairedresponseresponse to injuryrestorationtherapeutically effectivetranscriptomics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT ABSTRACT
Valvular aortic stenosis (VAS) accounts for approximately 3-6% of all congenital heart defects,1 and if left
untreated can lead to congestive heart failure in neonates and young infants. Non-invasive, percutaneous
balloon valvuloplasty (BVP) is the preferred first step of treatment in pediatrics with the intent to postpone
definitive surgery. Outcomes show that while BVP significantly reduces aortic valve (AoV) peak gradient within
the first 24 hours in the majority of patients, by the 2-3 year follow up more than half re-stenose and require
surgical intervention to repair or replace the dysmorphic and failing valve.2, 3 Therefore, while BVP is favorable
in some patients, others are diagnosed with poor clinical outcomes and it is not clear why.
Studies report that BVP can injure or even rupture the AoV,4, 5 and studies in rabbits have shown that
balloon inflation specifically injures the endothelium.6, 7 Furthermore, our work in mice strongly suggests that
direct injury to, or targeted dysfunction of the valve endothelium causes structural deterioration and functional
impairment of the AoV, consistent with histological studies in humans reporting poor endothelial integrity in
diseased valve tissue.8-11 Taken together, these studies suggest that endothelial damage is a significant
contributor of valve pathology, and this may underlie poor outcomes observed in VAS patients following BVP.
This raises the question: Can restoring endothelial function be an effective therapeutic strategy to treat structural
and functional deterioration of the AoV in susceptible individuals? To explore this, we developed a surgical
mouse model of AoV endothelial injury that causes structural and functional deterioration. Using this model, we
show that in response to injury, young healthy mice activate a beneficial intrinsic reparative response that leads
to endothelial restoration, while this response is impaired in aging mice with known endothelial dysfunction.12 In
addition, we propose a mechanism underlying these diverse responses. This proposal will test the overall
hypothesis that: The beneficial intrinsic reparative response of the injured valve endothelium requires Tgf1-
Cthrc1 signaling between valve endothelial, and underlying valve interstitial cells to promote proliferation and
migration of neighboring uninjured cells, leading to endothelial restoration.
To test this, we propose three specific aims: 1) Determine the cellular and molecular mechanisms
involved in the beneficial intrinsic response following AoV endothelial injury; 2) Determine the requirement of
endothelial-Tgf1 for the beneficial intrinsic reparative response of the injured AoV endothelium; and 3) Identify
interstitial-Cthrc1 as a critical factor for the beneficial intrinsic reparative response of the injured AoV
endothelium. Successful completion will define innovative mechanisms of the intrinsic reparative response as a
result of AoV endothelial injury that can be applied to the therapeutic design of mechanistic-based compounds
to promote endothelial restoration and prevent structural and functional deterioration, particularly in susceptible
individuals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Delineating the mechanisms underlying heart valve endothelial repair
-
批准号:10464257
-
项目类别:
-
资助金额:$45.07万
-
财政年份:2022
-
负责人:VOLKHARD LINDNER
-
依托单位:
Effect of CTHRC1 on endothelial cell survival after acute ischemia
-
批准号:10531574
-
项目类别:
-
资助金额:$53.46万
-
财政年份:2019
-
负责人:VOLKHARD LINDNER
-
依托单位:
Effect of CTHRC1 on endothelial cell survival after acute ischemia
-
批准号:9885606
-
项目类别:
-
资助金额:$53.46万
-
财政年份:2019
-
负责人:VOLKHARD LINDNER
-
依托单位:
Effect of CTHRC1 on endothelial cell survival after acute ischemia
-
批准号:10312789
-
项目类别:
-
资助金额:$53.46万
-
财政年份:2019
-
负责人:VOLKHARD LINDNER
-
依托单位:
Histopathology and Microscopy Core
-
批准号:10711695
-
项目类别:
-
资助金额:$31.09万
-
财政年份:2017
-
负责人:VOLKHARD LINDNER
-
依托单位:
Core C: Histopathology and Histomorphometry Core
-
批准号:10246814
-
项目类别:
-
资助金额:$16.9万
-
财政年份:2017
-
负责人:VOLKHARD LINDNER
-
依托单位:
CORE C: HISTOPATHOLOGY CORE
-
批准号:8360263
-
项目类别:
-
资助金额:$10.96万
-
财政年份:2011
-
负责人:VOLKHARD LINDNER
-
依托单位:
CORE C: HISTOPATHOLOGY CORE
-
批准号:8167686
-
项目类别:
-
资助金额:$10.56万
-
财政年份:2010
-
负责人:VOLKHARD LINDNER
-
依托单位:
CORE C: HISTOPATHOLOGY CORE
-
批准号:7960392
-
项目类别:
-
资助金额:$10.29万
-
财政年份:2009
-
负责人:VOLKHARD LINDNER
-
依托单位:
CONTROL OF VASCULAR FIBROSIS AND COLLAGEN DEPOSITION BY NOVEL REGULATOR, CTHRC-1
-
批准号:7959657
-
项目类别:
-
资助金额:$18.8万
-
财政年份:2009
-
负责人:VOLKHARD LINDNER
-
依托单位:
CONTROL OF VASCULAR FIBROSIS AND COLLAGEN DEPOSITION BY NOVEL REGULATOR, CTHRC-1
-
批准号:7720097
-
项目类别:
-
资助金额:$18.87万
-
财政年份:2008
-
负责人:VOLKHARD LINDNER
-
依托单位:
CORE C: HISTOPATHOLOGY CORE
-
批准号:7720703
-
项目类别:
-
资助金额:$11.06万
-
财政年份:2008
-
负责人:VOLKHARD LINDNER
-
依托单位:
CORE C: HISTOPATHOLOGY CORE
-
批准号:7610631
-
项目类别:
-
资助金额:$13.02万
-
财政年份:2007
-
负责人:VOLKHARD LINDNER
-
依托单位:
CONTROL OF VASCULAR FIBROSIS AND COLLAGEN DEPOSITION BY NOVEL REGULATOR, CTHRC-1
-
批准号:7609691
-
项目类别:
-
资助金额:$18.81万
-
财政年份:2007
-
负责人:VOLKHARD LINDNER
-
依托单位:
CONTROL OF VASCULAR FIBROSIS AND COLLAGEN DEPOSITION BY NOVEL REGULATOR, CRHRC-1
-
批准号:7381068
-
项目类别:
-
资助金额:$19.21万
-
财政年份:2006
-
负责人:VOLKHARD LINDNER
-
依托单位:
CORE C: HISTOPATHOLOGY CORE
-
批准号:7382096
-
项目类别:
-
资助金额:$15.96万
-
财政年份:2006
-
负责人:VOLKHARD LINDNER
-
依托单位:
COBRE: MAINE MED CTR: CORE C: PATHOLOGY CORE
-
批准号:7171325
-
项目类别:
-
资助金额:$19.42万
-
财政年份:2005
-
负责人:VOLKHARD LINDNER
-
依托单位:
CORE--PATHOLOGY
-
批准号:6981990
-
项目类别:
-
资助金额:$8.52万
-
财政年份:2004
-
负责人:VOLKHARD LINDNER
-
依托单位:
Remodelin, a Novel Vascular Injury and Bone Related Gene
-
批准号:6933808
-
项目类别:
-
资助金额:$30.52万
-
财政年份:2002
-
负责人:VOLKHARD LINDNER
-
依托单位:
Cthrc1 function as a novel TGF-beta antagonist in the vasculature
-
批准号:8419303
-
项目类别:
-
资助金额:$7.15万
-
财政年份:2002
-
负责人:VOLKHARD LINDNER
-
依托单位:
海外基金